<DOC>
	<DOCNO>NCT01505166</DOCNO>
	<brief_summary>Preliminary study variety vaccine suggest target accessibility ( potential immunogenicity ) variety solid tumor immune direct approach . In effort overcome limitation immunostimulatory cancer vaccine , Gradalis design novel autologous vaccine address inability fully identify cancer associate antigen , antigen recognition immune system ( i.e . antigen -- &gt; immunogen ) , effector potency , cancer-induced resistance . In effort overcome limitation immunostimulatory cancer vaccine , design novel dual-modulatory autologous whole cell vaccine , Vigil™ , incorporate rhGMCSF transgene bifunctional shRNAfurin ( block proprotein conversion active TGFb1 b2 ) 1 ) address inability fully identify cancer associate antigen , 2 ) effect antigen recognition immune system , 3 ) enhance effector potency , 4 ) subvert endogenous cancer-induced immune resistance . We also complete Phase I assessment Vigil™ vaccine 30 advance solid tumor patient ( 1.0 x 10^7 cells/injection/month maximum 12 vaccination ) experience significant adverse effect follow 144 vaccination , include 6 patient colorectal carcinoma . Plasmid functionality , immune biomarker response , preliminary evidence anticancer activity observe . This two-part Phase II study Vigil™ autologous vaccine . Six patient enrol Part 1 study receive intradermal autologous Vigil™ cancer vaccine ( 1.0 x 10^7 cells/injection ; maximum 12 vaccination ) . Part 2 study randomize Phase II study sandwich adjuvant chemotherapy intradermal autologous Vigil™ cancer vaccine ( 1.0 x 10^7 cells/injection ; maximum 12 vaccination ) versus sandwich adjuvant chemotherapy placebo patient colorectal carcinoma either synchronous metachronous liver metastasis ( CLM +/= pulmonary metastasis ) follow resection +/= ablation curative intent.Sandwich therapy indicate combination pre-operative postoperative chemotherapy oppose neo-adjuvant ( chemotherapy prior surgery ) adjuvant ( chemotherapy follow surgery ) therapy . A minimum harvest aliquot produce 4 monthly injection require entry study . Patients insufficient tissue ( &lt; 4 dos ) collect whose vaccine fail manufacture release criterion receive vaccine .</brief_summary>
	<brief_title>Randomized Phase II Adjuvant Chemotherapy ± FANG™ Colorectal Carcinoma With Liver Metastases</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Colonic Neoplasms</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Modafinil</mesh_term>
	<mesh_term>Armodafinil</mesh_term>
	<criteria>1 . Histologically confirm colorectal carcinoma synchronous metachronous liver metastasis +/ pulmonary metastasis . 2 . Part 1 patient : May multiple number metastatic lesion long render evidence disease ( NED ) . 3 . Part 2 patient : Maximum total number metastatic lesion &lt; /= 6 . ( Patients CLM EHD lung evaluate individual basis sponsor ) . 1 . For patient 1 3 total lesion , distribution must include liver + pulmonary metastasis . 2 . For patient 46 total lesion , distribution may include liver +/ pulmonary metastasis . 4 . Candidate surgical excision +/= ablation curative intent base preoperative assessment incorporate CT/PET scan . 5 . Has inform alternative ≥ first and/or secondline therapy current standard care . If conventional frontline therapy indicate acceptable patient , patient may participate review sponsor . 6 . Planned resect viable tumor sufficient quantity ( `` golf ball size '' estimate weight ~ 30 gram ) vaccine processing . 7 . Recovered ≤ Grade 1 ( exclude alopecia ) clinically relevant toxicity relate prior therapy . 8 . Patients must `` statin '' drug ≥ 2 week prior initiation therapy . 9 . Age ≥18 year . 10 . ECOG performance status ( PS ) 02 . 11 . Estimated &gt; 4 month survival probability . 12 . Normal organ marrow function define : Absolute granulocyte count ≥1,500/mm3 Absolute lymphocyte count ≥ 500/mm3 Platelets ≥100,000/mm3 Total bilirubin &lt; /=2 mg/dL AST ( SGOT ) /ALT ( SGPT ) &lt; /=2x institutional upper limit normal Creatinine &lt; 1.5 mg/dL 13 . Ability understand willingness sign write informed consent document . 14 . Negative pregnancy test . 1 . Surgery involve general anesthesia , radiotherapy , steroid therapy , immunotherapy within 4 week prior enter study . Collection lumenal tissue must avoid . 2 . Prior therapeutic chemotherapy ( exclude protocol define sandwich chemotherapy ) . Prior approve sandwich / adjuvant therapy permit maximum 3 cycle ( 1 cycle = 2 biweekly course / 1 month ) anterior therapy least 6 month cessation chemotherapy diagnosis metastatic disease . 3 . Prior surgical resection , ablation radiation therapy metastatic disease prior time tissue procurement . 4 . Portal , celiac periaortic metastasis . 5 . Patient must receive investigational agent within 30 day prior study entry/ registration . 6 . Patients know active symptomatic brain metastasis . 7 . Patients compromise pulmonary disease . 8 . Short term ( &lt; 30 day ) concurrent systemic steroid ≤ 0.125 mg/kg prednisone per day ( maximum 10 mg/day ) bronchodilator ( inhaled steroid ) permit ; steroid regimen and/or immunosuppressive exclude . 9 . Prior splenectomy . 10 . Prior malignancy ( exclude nonmelanoma carcinomas skin ) unless remission ≥ 2 year . 11 . Kaposi 's Sarcoma . 12 . Uncontrolled intercurrent illness include , limited ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . 13 . Patients know HIV . 14 . Patients chronic Hepatitis B C infection . 15 . Patients uncontrolled autoimmune disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>colorectal carcinoma</keyword>
	<keyword>colon cancer</keyword>
	<keyword>liver metastasis</keyword>
</DOC>